GlyTherix
  • Home
  • Company
  • Product Pipeline
  • For Investors
  • News
  • Contact Us
Select Page
High-Yield GMP-Compliant Primary Cell Bank Established for Miltuximab®

High-Yield GMP-Compliant Primary Cell Bank Established for Miltuximab®

by GlyTherix | Jul 21, 2022

Date, July 21 2022: Sydney. GlyTherix is pleased to announce the successful completion of its high-yield GMP-grade stable cell line development program for its proprietary antibody Miltuximab® in partnership with international biologics manufacturer GenScript ProBio...

Recent Posts

  • GPC-1 – a first-in-class “theranostic” oncology asset – The Evidence
  • GlyTherix Ltd signs Lutetium-177 supply agreement with ANSTO
  • GlyTherix seeks USD 10M in pre-IPO funding ahead of planned listing in 2024

RECENT POSTS

  • GPC-1 – a first-in-class “theranostic” oncology asset – The Evidence
  • GlyTherix Ltd signs Lutetium-177 supply agreement with ANSTO
  • GlyTherix seeks USD 10M in pre-IPO funding ahead of planned listing in 2024
  • GlyTherix and Adcendo Announce Agreement for Development of Antibody Drug Conjugate

ENQUIRIES

Address
Level 1, 3 Innovation Road,
Macquarie Park NSW 2113, Australia

Australian Business Number
66 621 291 996

MORE INFO

FOR SHAREHOLDERS:
Shareholder Communications Options

Would you like to talk with Glytherix about:

  • Investing in us?
  • Partnering with us?
  • Media events?
  • Some feedback?
  • Home
  • News
  • Terms of Use
  • Privacy Policy
  • Contact Us

COPYRIGHT 2023 | GLYTHERIX - ALL RIGHTS RESERVED